Psychiatry - August 2008 - (Page 24)

Trend Watch Sanofi, Sanofi-Synthelabo, Schwabe/Ingenix, Shire, Solvay, Synaptic, TAP, UCB Pharma, Validus, Vela, and Wyeth; and has been or is a stockholder in Bristol-Myers Squibb, Cortex, Merck, and Pfizer. ABSTRACT: Primary care physicians, pediatricians, and psychiatrists account for approximately 80 percent of attention deficit hyperactivity disorder (ADHD) treatments prescribed in the United States. Selection of short-acting versus long-acting ADHD treatment varies by specialty with long-acting agents representing 56 percent of primary care prescriptions, 64 percent of psychiatrist prescriptions, and 79 percent of pediatric prescriptions. There appears to be a correlation between short-acting versus long-acting treatment selection and age, with long-acting agents accounting for 78 percent of prescriptions for pediatric patients (age 0–17) but only 49 percent of prescriptions for adults (patients aged 18+). A discussion of data is included. Short-acting versus Long-acting Medications for the Treatment of ADHD by Elisa Cascade; Amir H. Kalali, MD; and Richard H. Weisler, MD KEY WORDS: ADHD medication, attention deficit hyperactivity disorder, long-acting formulation, short-acting formulation, stimulant, prescription INTRODUCTION In this article, we explore use of long-acting versus short-acting treatment for attention deficit hyperactivity disorder (ADHD) by primary care physicians, pediatricians, and psychiatrists. Variation in treatment selection by patient age is also investigated. Psychiatry (Edgemont) 2008;5(8):24–27 AUTHOR AFFILIATIONS: Ms. Cascade is Vice President, Quintiles Inc./iGuard, Falls Church, Virginia; Dr. Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles Inc., San Diego, California, and Professor of Psychiatry, University of California, San Diego; and Dr. Weisler is an Adjunct Professor of Psychiatry at the University of North Carolina, Chapel Hill and Adjunct Associate Professor of Psychiatry at Duke University, Durham, North Carolina. ADDRESS CORRESPONDENCE TO: Ms. Elisa Cascade, Vice President, Quintiles, Inc./iGuard, 3130 Fairview Park Drive, Suite 501, Falls Church, VA 22042; E-mail: elisa.cascade@quintiles.com FINANCIAL DISCLOSURES: Dr. Weisler is or has been a consultant to, on the speakers bureaus of, and/or received research support from the National Institute of Mental Health, Abbott, AstraZeneca, Biovail, Bristol-Myers Squibb, Burroughs Wellcome, Cephalon, Ciba Geigy, CoMentis, Corcept, Eisai, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Johnson & Johnson, Lundbeck, McNeil Pharmaceuticals, Medicinova, Merck, Neurochem, New River Pharmaceuticals, Novartis, Organon, Otsuka America Pharma, Pfizer, Pharmacia, Saegis, METHODS We obtained data on total retail prescriptions for ADHD medications in March, April, and May 2008 from Verispan’s Vector One National (VONA), which captures nearly half of all prescription activity in the US. Individual products were classified as short acting, medium acting, or long acting as follows: • Short acting: amphetamine/dextroamphetamine (Adderall), dextroamphetamine 24 Psychiatry 2008 [ A U G U S T ]

Table of Contents Feed for the Digital Edition of Psychiatry - August 2008

Psychiatry - August 2008 Editor’s Message Editorial Advisory Board Contents Borderline Personality Disorder: Are Proliferative Symptoms Characteristic? Short-acting versus Long-acting Medications for the Treatment of ADHD Baby Stimuli and the Parent Brain: Functional Neuroimaging of the Neural Substrates of Parent-Infant Attachment These Boots Are Made for Stalking: Characteristics of Female Stalkers Managing Attention Deficit Hyperactivity Disorder in the Emergency Department Obstructive Sleep Apnea, Hypoxia, and Metabolic Syndrome in Psychiatric and Nonpsychiatric Settings Improving the Quality of Life in Patients with Alzheimer’s Disease The Process of Getting New Drugs to Market Journal Watch Classified Advertising Information for Authors

Psychiatry - August 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.